mTORC1 and mTORC2 Levels in Patients with Psoriasis.

INTRODUCTION

In recent years, there has been a growing emphasis on the role of the mammalian target of rapamycin (mTOR) pathway in the pathogenesis of psoriasis. This intracellular signaling pathway is known as the main control pathway of metabolism and is of particular interest in this context.

OBJECTIVES

To investigate the importance of the mTOR pathway in the pathogenesis of plaque psoriasis.

METHODS

A total of forty patients with plaque psoriasis and 40 non-psoriatic volunteers were included in this case-control study. The fasting serum levels of mTORC1 and mTORC2 in the study groups were examined by enzyme-linked immunosorbent assay.

RESULTS

Serum levels of both mTORC1 and mTORC2 were found to be significantly lower in patients with plaque psoriasis than in controls (P = 0.001). A positive correlation was identified between serum mTORC1 and serum mTORC2 levels in patients with plaque psoriasis (p=0.001, r=0.826).

CONCLUSION

The lower serum levels of mTORC1 and mTORC2 complexes, which are active signaling molecules in the cell, were observed in patients with plaque psoriasis. This suggests that these levels may serve as an indicator of increased intracellular activation of these molecules. It is our opinion that agents that can effectively inhibit both mTOR complexes may be more effective in the treatment of psoriasis.